Payment overview · 2025
General Payments
$658.72
30 reported records · 17 companies
Healthcare provider profile · identity verified
Mehandar Kumar, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · KEANSBURG, NJ · NPI 1790082550
Verified facts
What the public records show
CMS Open Payments records show Mehandar Kumar, M.D received $658.72 in general payments during 2025 across 30 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 26.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Farxiga by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $172.32 | 26.2% | 4 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $84.07 | 12.8% | 5 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $59.77 | 9.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $58.36 | 8.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.86 | 5.1% | 2 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $31.42 | 4.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.49 | 4.6% | 1 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.67 | 3.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.50 | 3.4% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $21.33 | 3.2% | 1 | 2025 |
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $19.00 | 2.9% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $18.99 | 2.9% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $18.18 | 2.8% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $17.48 | 2.6% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $17.14 | 2.6% | 1 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $15.97 | 2.4% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $15.17 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $658.72 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $172.32 | 4 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $59.77 | 3 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Biological, Drug | ABBVIE INC., Genentech USA, Inc. | $51.82 | 2 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $38.22 | 2 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $38.10 | 2 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $32.05 | 2 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $31.42 | 2 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $31.42 | 2 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| Zoladex Normalized: zoladex |
Drug | TerSera Therapeutics LLC | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
108 | 23 |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
132 | 32 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
132 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 399 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 357 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 236 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 221 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 205 | 64 |
| Prednisone | Prednisone | 198 | 104 |
| Metformin Hcl | Metformin Hcl | 193 | 68 |
| Furosemide | Furosemide | 182 | 57 |
| Omeprazole | Omeprazole | 182 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 173 | 59 |
| Losartan Potassium | Losartan Potassium | 173 | 54 |
| Montelukast Sodium | Montelukast Sodium | 155 | 44 |
| Gabapentin | Gabapentin | 153 | 51 |
| Lisinopril | Lisinopril | 142 | 51 |
| Eliquis | Apixaban | 132 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 129 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 117 | 42 |
| Azithromycin | Azithromycin | 113 | 85 |
| Glipizide Er | Glipizide | 113 | 29 |
| Meloxicam | Meloxicam | 111 | 52 |
| Farxiga | Dapagliflozin Propanediol | 108 | 23 |
| Simvastatin | Simvastatin | 100 | 31 |
| Trazodone Hcl | Trazodone Hcl | 87 | 27 |
| Sertraline Hcl | Sertraline Hcl | 80 | 19 |
| Alprazolam | Alprazolam | 71 | 32 |
| Glimepiride | Glimepiride | 71 | 20 |
| Mirtazapine | Mirtazapine | 70 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 67 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 65 | 27 |
| Ozempic | Semaglutide | 65 | 12 |
| Carvedilol | Carvedilol | 64 | 22 |
| Januvia | Sitagliptin Phosphate | 64 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 22 |
| Famotidine | Famotidine | 63 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 14 |
| Mounjaro | Tirzepatide | 60 | 14 |
| Potassium Chloride | Potassium Chloride | 57 | 16 |
| Allopurinol | Allopurinol | 53 | 19 |
| Amoxicillin | Amoxicillin | 53 | 42 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 52 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 29 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 11 |
| Tramadol Hcl | Tramadol Hcl | 47 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 13 |
| Xarelto | Rivaroxaban | 45 | 11 |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 20 |
| Methylprednisolone | Methylprednisolone | 43 | 38 |
| Temazepam | Temazepam | 42 | suppressed |
| Lovastatin | Lovastatin | 41 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 13 |
| Ibuprofen | Ibuprofen | 39 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 34 |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 12 |
| Finasteride | Finasteride | 33 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 33 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 27 |
| Promethazine Hcl | Promethazine Hcl | 31 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 27 |
| Spironolactone | Spironolactone | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 29 | 21 |
| Meclizine Hcl | Meclizine Hcl | 29 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | 11 |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 18 |
| Bupropion Xl | Bupropion Hcl | 26 | 12 |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Glipizide | Glipizide | 26 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 13 |
| Celecoxib | Celecoxib | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Keytruda | Pembrolizumab | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 14 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 14 |
| Atenolol | Atenolol | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Azor | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 11 | 11 |
| Revlimid | Lenalidomide | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $658.72 · 30 records | E.R. Squibb & Sons, L.L.C. | BALVERSA, DARZALEX, DATROWAY, ERLEADA, FOTIVDA, Fabhalta, INQOVI, JAKAFI, JEMPERLI, LIBTAYO, LONSURF, Lenvima, MONOFERRIC, OJJAARA, OPDIVO, REBLOZYL, SARCLISA, TALVEY, TECVAYLI, VENCLEXTA, ZEJULA, Zoladex | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error